PhaseBio Pulls Plug On Mid-Stage Hypertension Asset

PhaseBio Pharmaceuticals Inc PHAS is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH).

  • The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study. 
  • The Company will analyze the trial data to determine an appropriate path forward for the program. 
  • Related: PhaseBio Says Antiplatelet Candidate Achieved Primary Reversal Endpoint In Late-Stage Study.
  • With the suspension of the Phase 2b trial, the Company will reprioritize resources and capital towards pre-commercialization activities of bentracimab and the advancement of other pipeline programs. 
  • The Phase 2b trial of pemziviptadil had enrolled more than 50% of the study's target population.
  • Pemziviptadil is a subcutaneously injected VIP analog, a recombinant fusion protein composed of VIP and PhaseBio's proprietary elastin-like polypeptide (ELP) biopolymer. 
  • Price Action: PHAS shares are down 0.80% at $2.48 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!